The risk or severity of adverse effects can be increased when Nicergoline is combined with Rabeprazole. The risk or severity of adverse effects can be increased when Methysergide is combined with Rabeprazole. The metabolism of Ketamine can be decreased when combined with Rabeprazole. The metabolism of Cisapride can be decreased when combined with Rabeprazole. The serum concentration of Saquinavir can be increased when it is combined with Rabeprazole. The metabolism of Rabeprazole can be decreased when combined with Topiramate. The serum concentration of Rabeprazole can be increased when it is combined with Fusidic Acid. The metabolism of Carbinoxamine can be decreased when combined with Rabeprazole. Rabeprazole can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects. The metabolism of Azelastine can be decreased when combined with Rabeprazole. Rabeprazole can cause an increase in the absorption of Amphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects. The serum concentration of the active metabolites of Dabigatran etexilate can be reduced when Dabigatran etexilate is used in combination with Rabeprazole resulting in a loss in efficacy. The metabolism of Rabeprazole can be decreased when combined with Armodafinil. The metabolism of Dapsone can be decreased when combined with Rabeprazole. The metabolism of Rabeprazole can be decreased when combined with Eslicarbazepine acetate. The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Rabeprazole. The serum concentration of Rabeprazole can be decreased when it is combined with Deferasirox. Rabeprazole can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy. The metabolism of Testosterone can be decreased when combined with Rabeprazole. The serum concentration of Mevastatin can be increased when it is combined with Rabeprazole. The risk or severity of adverse effects can be increased when Bromocriptine is combined with Rabeprazole. The metabolism of Rabeprazole can be decreased when combined with Cholecalciferol. The metabolism of Rabeprazole can be decreased when combined with Ticlopidine. The metabolism of Acetylsalicylic acid can be decreased when combined with Rabeprazole. The metabolism of Amitriptyline can be decreased when combined with Rabeprazole. The metabolism of Troglitazone can be decreased when combined with Rabeprazole. The metabolism of Naproxen can be decreased when combined with Rabeprazole. The serum concentration of Pazopanib can be increased when it is combined with Rabeprazole. The serum concentration of Rabeprazole can be decreased when it is combined with St. John's Wort. The metabolism of Naloxone can be decreased when combined with Rabeprazole. The metabolism of Tretinoin can be decreased when combined with Rabeprazole. The metabolism of Quinidine can be decreased when combined with Rabeprazole. The metabolism of Antipyrine can be decreased when combined with Rabeprazole. The metabolism of Tolbutamide can be decreased when combined with Rabeprazole. The metabolism of Rabeprazole can be decreased when combined with Clemastine. The serum concentration of Riociguat can be decreased when it is combined with Rabeprazole. The metabolism of Rabeprazole can be increased when combined with Carbamazepine. The metabolism of Rabeprazole can be increased when combined with Rifampicin. The serum concentration of Rabeprazole can be increased when it is combined with Fosaprepitant. The metabolism of Perphenazine can be decreased when combined with Rabeprazole. The therapeutic efficacy of Pamidronate can be decreased when used in combination with Rabeprazole. The metabolism of Rabeprazole can be decreased when combined with Ranolazine. The serum concentration of Rabeprazole can be increased when it is combined with Ivacaftor. The metabolism of Ixazomib can be decreased when combined with Rabeprazole. The metabolism of Selexipag can be decreased when combined with Rabeprazole. The metabolism of Loperamide can be decreased when combined with Rabeprazole. The metabolism of Rabeprazole can be decreased when combined with Venlafaxine. The metabolism of Mirtazapine can be decreased when combined with Rabeprazole. The therapeutic efficacy of Zoledronic acid can be decreased when used in combination with Rabeprazole. The metabolism of Rabeprazole can be decreased when combined with Verapamil. The metabolism of Nicotine can be decreased when combined with Rabeprazole. The metabolism of Cyclophosphamide can be decreased when combined with Rabeprazole. The metabolism of Rabeprazole can be decreased when combined with Darunavir. The risk or severity of adverse effects can be increased when Ergonovine is combined with Rabeprazole. The serum concentration of Methotrexate can be increased when it is combined with Rabeprazole. The serum concentration of Rabeprazole can be increased when it is combined with Osimertinib. The metabolism of Zidovudine can be decreased when combined with Rabeprazole. The therapeutic efficacy of Mesalazine can be decreased when used in combination with Rabeprazole. The metabolism of Rabeprazole can be decreased when combined with Isradipine. The metabolism of Ibuprofen can be decreased when combined with Rabeprazole. The metabolism of Rabeprazole can be decreased when combined with Sulfisoxazole. The metabolism of Pioglitazone can be decreased when combined with Rabeprazole. The metabolism of Seratrodast can be decreased when combined with Rabeprazole. The metabolism of Sitagliptin can be decreased when combined with Rabeprazole. The metabolism of Rabeprazole can be decreased when combined with Imatinib. The metabolism of Tazarotene can be decreased when combined with Rabeprazole. The metabolism of Rabeprazole can be decreased when combined with Clotrimazole. The metabolism of Aminophenazone can be decreased when combined with Rabeprazole. The metabolism of Buprenorphine can be decreased when combined with Rabeprazole. The metabolism of Almotriptan can be decreased when combined with Rabeprazole. The serum concentration of Mycophenolic acid can be decreased when it is combined with Rabeprazole. The metabolism of Loratadine can be decreased when combined with Rabeprazole. The metabolism of Rabeprazole can be decreased when combined with Lovastatin. The serum concentration of Dabrafenib can be decreased when it is combined with Rabeprazole. The metabolism of Levomilnacipran can be decreased when combined with Rabeprazole. The metabolism of Ifosfamide can be decreased when combined with Rabeprazole. Rabeprazole can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy. The metabolism of Morphine can be decreased when combined with Rabeprazole. The therapeutic efficacy of Risedronate can be decreased when used in combination with Rabeprazole. The metabolism of Ombitasvir can be decreased when combined with Rabeprazole. The metabolism of Mefenamic acid can be decreased when combined with Rabeprazole. The serum concentration of Thioridazine can be increased when it is combined with Rabeprazole. The metabolism of Brigatinib can be decreased when combined with Rabeprazole. The metabolism of Rabeprazole can be decreased when combined with Lobeglitazone. The metabolism of Rabeprazole can be decreased when combined with Efavirenz. The serum concentration of Risedronate can be increased when it is combined with Rabeprazole. The serum concentration of Cilostazol can be increased when it is combined with Rabeprazole. The serum concentration of Itraconazole can be decreased when it is combined with Rabeprazole. The metabolism of Rosiglitazone can be decreased when combined with Rabeprazole. The metabolism of Temazepam can be decreased when combined with Rabeprazole. The metabolism of Rabeprazole can be decreased when combined with Esomeprazole. Rabeprazole can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy. The metabolism of Piroxicam can be decreased when combined with Rabeprazole. The metabolism of Rabeprazole can be decreased when combined with Zucapsaicin. The metabolism of Dasabuvir can be decreased when combined with Rabeprazole. The metabolism of Pentamidine can be decreased when combined with Rabeprazole. The metabolism of Theophylline can be decreased when combined with Rabeprazole. The serum concentration of Rabeprazole can be increased when it is combined with Luliconazole. The serum concentration of Rabeprazole can be decreased when it is combined with Vemurafenib. The metabolism of Eszopiclone can be decreased when combined with Rabeprazole. The metabolism of Propofol can be decreased when combined with Rabeprazole. The metabolism of Rabeprazole can be increased when combined with Rifapentine. The serum concentration of Rabeprazole can be decreased when it is combined with Mitotane. The metabolism of Velpatasvir can be decreased when combined with Rabeprazole. The metabolism of Rabeprazole can be decreased when combined with Omeprazole. The metabolism of Brompheniramine can be decreased when combined with Rabeprazole. The serum concentration of Metoprolol can be increased when it is combined with Rabeprazole. The serum concentration of Posaconazole can be decreased when it is combined with Rabeprazole. The serum concentration of Erlotinib can be decreased when it is combined with Rabeprazole. The serum concentration of Nilotinib can be decreased when it is combined with Rabeprazole. The metabolism of Rabeprazole can be decreased when combined with Lopinavir. The metabolism of Rabeprazole can be decreased when combined with Dronedarone. The metabolism of Rabeprazole can be decreased when combined with Abiraterone. The risk or severity of adverse effects can be increased when Methylergometrine is combined with Rabeprazole. The metabolism of Perospirone can be decreased when combined with Rabeprazole. The metabolism of Caffeine can be decreased when combined with Rabeprazole. The metabolism of Paclitaxel can be decreased when combined with Rabeprazole. The therapeutic efficacy of Rabeprazole can be decreased when used in combination with Sarilumab. The metabolism of Diazepam can be decreased when combined with Rabeprazole. Rabeprazole can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy. The metabolism of Rabeprazole can be decreased when combined with Crizotinib. The metabolism of Acetaminophen can be decreased when combined with Rabeprazole. The serum concentration of the active metabolites of Nelfinavir can be reduced when Nelfinavir is used in combination with Rabeprazole resulting in a loss in efficacy. The metabolism of Irbesartan can be decreased when combined with Rabeprazole. The serum concentration of Conivaptan can be increased when it is combined with Rabeprazole. The metabolism of Rabeprazole can be decreased when combined with Sildenafil. The serum concentration of Rabeprazole can be increased when it is combined with Palbociclib. The therapeutic efficacy of Clodronic Acid can be decreased when used in combination with Rabeprazole. The metabolism of Terbinafine can be decreased when combined with Rabeprazole. The metabolism of Rabeprazole can be increased when combined with Phenobarbital.